Close Asset Management’s Spero Therapeutics SPRO Stock Holding History

Close Asset Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10	Closed	–	–	222
2021 Q1	$0	Buy	+10	New	+$176	﹤0.01%	224

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Close Asset Management's SPRO Position: Q2 2021 in Review

Close Asset Management sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 10 shares.

Close Asset Management first reported a position in SPRO in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

Close Asset Management reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
Close Asset Management sold 10 Spero Therapeutics shares in Q2 2021.
Close Asset Management first reported a position in Spero Therapeutics in Q1 2021 and held it in 1 quarter.
Close Asset Management's Spero Therapeutics position peaked at $0 in Q1 2021.
88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on Close Asset Management's 13F filing for Q2 2021, filed 27 Jul 2021.